MagQu

MagQu is a Taiwan-based in vitro diagnostics and medical device company developing ultra-sensitive biomarker assays and analyzers based on its proprietary ImmunoMagnetic Reduction (IMR) technology. The company commercializes magnetic immunoassay analyzers, reagent kits, magnetic beads, and assay services for research and clinical applications, with particular emphasis on blood-based biomarkers for neurodegenerative disease. Its marketed menu includes assays for Alzheimer's disease-related biomarkers such as amyloid beta 1-40, amyloid beta 1-42, tau, and p-Tau181, as well as Parkinson's disease and frontotemporal dementia markers including alpha-synuclein, phospho-alpha-synuclein, and TDP-43. MagQu also offers OEM/ODM assay development and magnetic bead services, positioning itself as both a product company and an enabling platform provider. The business appears to be private, active, and internationally commercialized across parts of Asia, Europe, and the United States through its Taiwan operations and U.S. affiliate.